Spotlight Growth
No Result
View All Result
Tuesday, August 16, 2022
  • Login
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

Cumberland Pharmaceuticals, Inc.’s (NASDAQ: CPIX) Caldolor Pain Reliever Receives FDA Approval for Pre-Operation Administration

by admin
November 30, 2021
in Bio/Med/Pharma
0
Cumberland Pharmaceuticals NASDAQ CPIX FDA Caldolor Spotlight Growth

Cumberland Pharmaceuticals NASDAQ CPIX FDA Caldolor Spotlight Growth

Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) is engaged as a specialty pharmaceutical company, which is focused on development and delivery of high-quality prescription medications. The pharmaceutical company’s pipeline covers hospital acute care, gastroenterology, and rheumatology. Shares of the specialty pharmaceutical company are skyrocketing 121% through early trading on Tuesday, November 30, 2021. Over the past three months, Cumberland Pharmaceuticals has seen average daily volume of 326,830 shares. However, volume of 94.17 million shares or dollar volume of around $486.86 million, has already exchanged hands through afternoon trading Tuesday.

Shares of Cumberland Pharmaceuticals are surging Tuesday, after the company announced that the U.S. Food and Drug Administration (FDA) has approved expanded labeling for the company’s Caldolor pain reliever for use during pre-operation. Caldolor is an intravenously-delivered ibuprofen formula. The FDA ruling allows health care professionals to administer Caldolor to patients preparing for surgery. This helps the patients to wake up from surgery with “significantly less pain,” according to the company.

The study supporting the FDA’s decision featured a total of 185 patients randomly treated with either 800mg of Caldolor or a placebo, over a six-hour period. Cumberland Pharmaceuticals says efficacy of Caldolor was clearly demonstrated as the treatment group faced a greater reduction in pain over the first 24 hours post-surgery, compared to the placebo.

“Before the pandemic began, healthcare systems across the country were in the midst of a public health mission to control surgical pain while decreasing opioid consumption,” said A.J. Kazimi, chief executive officer of Cumberland Pharmaceuticals Inc. “We are proud to see the continued support for Caldolor’s use in surgical care, with the product’s approved labeling now including the expanded use of the product prior to surgery. We feel confident that this important development provides additional insights into how intravenous ibuprofen can help healthcare professionals and patients as elective surgeries resume.”

Disclosure: Neither Spotlight Growth nor its officers have any position or relationship with any companies mentioned in this article, but may choose to initiate a position at any time. No payment was made to create this article. This article should not be taken as a solicitation or recommendation to buy or sell any securities. Please conduct your own research and consult your financial advisor to determine your risk tolerance and investment path. We are not licensed brokers or investment advisors.

Tags: biopharmaceuticalsbiotechbiotechnology stocksCaldolorcommon stockCPIXCPIX stockCumberland Pharmaceuticalsday tradingemerging growthFDAhealthhealth care stocksinvestinginvesting newsinvestmentmedicalmedical stocksmicrocap stocksNASDAQnasdaq biotech stocksnewspain reliefpharmapharmaceuticalspublic companyRobinhoodrobinhood armyrobinhood stockssalesservicessmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstock market newsstocksstocks to watchtradingtreatment
Plugin Install : Widget Tab Post needs JNews - View Counter to be installed
  • Trending
  • Comments
  • Latest
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

November 22, 2021
Alfi NASDAQ ALF Ridesharing Tablet Rollout Spotlight Growth

Alfi, Inc. (NASDAQ: ALF) Climbs 51% After Entering Into Agreement with Miami-Based Fulfillment & Distribution Center For its Ridesharing Digital Tablet Rollout

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
OLB Group NASDAQ OLB Q2 2022 Earnings Results Spotlight Growth

OLB Group (NASDAQ: OLB) Continues Record Revenue Growth for 2022

August 15, 2022
Viridian Therapeutics NASDAQ VRDN TED Phase 1 2 Clinical Trial Data Spotlight Growth

Viridian Therapeutics (NASDAQ: VRDN) Shares Positive Clinical Data from Phase 1/2 Trial of VRDN-001 for Treatment of Thyroid Eye Disease

August 15, 2022
Twin Vee PowerCats NASDAQ VEEE Q2 2022 Financial Results Spotlight Growth

Twin Vee PowerCats (NASDAQ: VEEE) Releases Q2 2022 Results Showing 158% Increase in Revenue, Completes Spin-Off of Forza X1 (NASDAQ: FRZA)

August 12, 2022
Is Uber Technologies NYSE UBER Finally Investible Spotlight Growth

Is Uber (NYSE: UBER) Finally Investable?

August 11, 2022

Recent News

OLB Group NASDAQ OLB Q2 2022 Earnings Results Spotlight Growth

OLB Group (NASDAQ: OLB) Continues Record Revenue Growth for 2022

August 15, 2022
Viridian Therapeutics NASDAQ VRDN TED Phase 1 2 Clinical Trial Data Spotlight Growth

Viridian Therapeutics (NASDAQ: VRDN) Shares Positive Clinical Data from Phase 1/2 Trial of VRDN-001 for Treatment of Thyroid Eye Disease

August 15, 2022

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us
Spotlight Growth

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested